Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 clinical trial to evaluate inobrodib in combination with Teclistamab or Elranatamab for the treatment of relapsed/refractory multiple myeloma

Next Previous
Trial Profile

Phase 1/2 clinical trial to evaluate inobrodib in combination with Teclistamab or Elranatamab for the treatment of relapsed/refractory multiple myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Oct 2025 New trial record
  • 03 Sep 2025 According to CellCentric media release, the company announced that it has initiated dosing in new cohorts evaluating inobrodib in combination with B-cell maturation antigen (BCMA) directed CD3 T-cell engagers.Initial safety data expected by year end.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top